论文部分内容阅读
目的:观察希罗达单药治疗转移性乳腺癌的近期疗效和不良反应。方法:希罗达单药2500mg/(m2·d),分早晚两次,餐后服用。连续服用2周,休息1周为1个周期。每例患者至少进行2个周期的治疗。结果:36例可评价疗效和不良反应的患者中,无完全缓解(CR)患者,部分缓解(PR)14例,总有效率38.9%;病情稳定(SD)16例,占44.4%;病情进展(PD)6例,占16.7%。临床获益患者(CR+PR+SD)共30例,占83.3%。主要不良反应为手足综合征,共22例占61.1%,厌食、恶心、腹胀、腹泻、骨髓抑制少,中性粒细胞减少的发生率28.0%。结论:应用希罗达口服治疗转移性乳腺癌有效,发生的手足综合征多可耐受,骨髓抑制轻,口炎发生率低。
Objective: To observe the recent efficacy and side effects of Xeloda monotherapy in the treatment of metastatic breast cancer. Methods: Xeloda single 2500mg / (m2 · d), points twice a day, after meals. Take 2 consecutive weeks, 1 week rest for 1 cycle. Each patient is treated for at least 2 cycles. Results: Among the 36 patients with complete response (CR), there were 14 patients with complete remission (CR), the total effective rate was 38.9%; 16 patients were stable (SD), accounting for 44.4%; the progression of the disease (PD) in 6 cases, accounting for 16.7%. Clinical benefit patients (CR + PR + SD) a total of 30 cases, accounting for 83.3%. The main adverse reactions were hand-foot syndrome, a total of 22 cases accounted for 61.1%, anorexia, nausea, bloating, diarrhea, bone marrow suppression less, the incidence of neutropenia was 28.0%. Conclusion: The application of Xeloda oral treatment of metastatic breast cancer effective, more than hand-foot syndrome can be tolerated, myelosuppression light, low incidence of stomatitis.